Milestone Pharmaceuticals enrolls first patient in Phase 3 ReVeRA-301 trial of etripamil nasal spray for AFib-RVR
MIST•First patient enrolled in Phase 3 ReVeRA-301
Milestone Pharmaceuticals enrolled the first patient in ReVeRA-301, a pivotal Phase 3 trial of etripamil nasal spray for AFib-RVR.
No Phase 3 results have been presented; the study will generate future data to support a potential label expansion beyond its PSVT use.
The program targets a self-administered option intended to reduce emergency-care reliance for rapid-rate atrial fibrillation episodes.
Development builds on earlier Phase 2 findings that indicated better symptom relief, improved patient satisfaction, and reduced heart-rate burden.
